Pamela L. Kunz, MD

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the most recent

(lutetium [Lu 177]&nbsp;dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.

The agent was approved by the FDA in 2018 for the treatment of patients with somatostatin receptorpositive GEP-NETs. Lutetium 177 is a radiolabeled somatostatin analog, says Kunz. The agent is given to patients by intravenous infusion for 4 doses.

Lutetium 177 represents a new class of therapy across all oncology. Kunz says there is a target on NET cells called the somatostatin receptor, and this receptor is the target for peptides like octreotide. She describes this as a lock and key scenario, where the receptor is the lock while the peptide acts as a key, bringing lutetium 177 along with it.

Videos

Pamela L. Kunz, MD, discusses the most recent FDA approval of Lutathera (lutetium [Lu 177] dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.

FDA-Approved Novel Agent Appears Promising in GEP-NETs

Pamela L. Kunz, MD, assistant professor of medicine (oncology), Stanford University Medical Center, discusses managing the adverse event of diarrhea in patients with carcinoid syndrome, specifically with the use of telotristat ethyl (Xermelo) during the 10th Annual NANETS Symposium.


Managing Diarrhea in Patients With Carcinoid Syndrome

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses classifying neuroendocrine tumors (NETs) and the potential to predict response.

Back to the Gastrointestinal Cancers Symposium conference page

Articles

Pamela L. Kunz, MD, discusses classifying neuroendocrine tumors (NETs) and the potential to predict response.

Classifying and Predicting Response in NETs

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the sequencing of agents for pancreatic neuroendocrine tumors (NETs).

Learn more about research into the treatment of pancreatic NETs > >

Sequencing Agents for the Treatment of Pancreatic NETs

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, on the use of angiogenesis inhibitors for the treatment of metastatic gastric cancer.

It has long been a question as to whether anti-angiogenesis agents could add benefit to a backbone of cytotoxic chemotherapy for the treatment of metastatic gastric cancer.

The AVAGAST study, which analyzed bevacizumab plus chemotherapy as first-line therapy in advanced gastric cancer, did not achieve its primary endpoint of improving median survival.

A small, single-arm phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma did not meet its primary endpoint of an improvement in PFS. Median PFS was 8.5 months and median OS was 14.3 months.

Angiogenesis Inhibitors for the Treatment of Metastatic Gastric Cancer

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the need to identify molecular subtypes of gastric cancer.